Adial Pharmaceuticals, INC.: management transactions · United States · SEC (Form 4)

About Adial Pharmaceuticals, INC.

Adial Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker ADIL in the United States. For French-speaking investors, it is best viewed as a development-stage healthcare name rather than a commercial-stage drug company. The business is headquartered in Glen Allen, Virginia, and its roots go back to ADial Pharmaceuticals, L.L.C., which was formed in November 2010 before later becoming a public corporation. Over time, Adial has built a focused clinical pipeline around addiction and related disorders. The company’s core activity is the development of therapies for the treatment and prevention of alcohol use disorder and other addiction-related conditions. Its lead investigational asset is AD04, a serotonin-3 receptor antagonist being studied for Alcohol Use Disorder (AUD). Adial has positioned AD04 within a precision-medicine framework, emphasizing biomarker-based patient selection and a potentially differentiated approach to treatment. That matters strategically because the addiction-treatment market remains medically underserved, and successful drug development in this area could address a meaningful unmet need. From a competitive standpoint, Adial sits in the small-cap biotech segment, where valuation is driven primarily by clinical milestones, regulatory progress, and access to capital. Its potential strengths include a narrow therapeutic focus and a lead asset aimed at a large and persistent public-health problem. However, the company also faces the usual biotech constraints: competition from larger pharmaceutical groups, uncertainty around clinical outcomes, and the need to secure financing before any meaningful product revenue can materialize. Until a product is approved and commercialized, Adial remains a high-risk, binary-outcome investment profile. Geographically, the company’s operations are primarily U.S.-centered, and its corporate and regulatory footprint is firmly based in the United States. Recent company updates indicate that Adial has been advancing its FDA dialogue and preparing for a planned Phase 3 program for AD04, while also discussing potential partnering opportunities. A notable recent development came in February 2026, when the company announced that it had regained compliance with Nasdaq’s minimum bid-price requirement after earlier pressure on the share price and a reverse stock split. That episode underscores the company’s financing sensitivity and market volatility. Overall, Adial Pharmaceuticals is a specialized NASDAQ-listed U.S. biotech company with a single lead program, a clear focus on addiction medicine, and a risk-return profile typical of clinical-stage pharmaceutical developers: significant upside tied to regulatory and clinical success, but substantial execution, funding, and dilution risk along the way.